{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-041264","form_type":"8-K","ticker":null,"cik":"0001397702","company_name":"Silk Road Medical Inc","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.908373+00:00","generated_at":"2026-05-31T04:13:34.490909+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.03","2.04","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Boston Scientific closes acquisition of Silk Road Medical for $27.50 per share","bullets":["Merger closed on September 17, 2024; shareholders received $27.50 per share in cash.","Silk Road became a wholly owned subsidiary of Boston Scientific; stock delisted from Nasdaq.","Previous board and officers (including CEO Charles McKhann) replaced by Boston Scientific appointees.","Existing loan agreement with Oxford Finance repaid in full with 1% prepayment fee; success fee paid to Stifel Bank.","Company will file Form 15 to terminate SEC reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-041264","json":"https://secwatch.observer/filing/0001140361-24-041264.json","markdown":"https://secwatch.observer/filing/0001140361-24-041264.md","text":"https://secwatch.observer/filing/0001140361-24-041264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041264/0001140361-24-041264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041264/ef20035938_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:13:34.490909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bafc71ddf369fd67f6d021c2607ce1a2536a5ad8","claim":"Silk Road Medical Inc underwent a change of control involving Boston Scientific Corporation for $27.50 in cash (closed 2024-09-17).","evidence_excerpt":"prior to the Effective Time (subject to certain customary exceptions specified in the Merger Agreement) was cancelled and converted automatically into the right to receive $27.50 in cash, without interest (the “Merger Consideration”) and subject to applicable taxes. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041264/0001140361-24-041264-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Boston Scientific Corporation"},{"label":"Consideration","value":"$27.50 in cash"},{"label":"Closing","value":"2024-09-17"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}